Cipher Pharmaceuticals (TSE:CPH) Releases Earnings Results

Cipher Pharmaceuticals (TSE:CPH) (NASDAQ:CPHR) issued its quarterly earnings results on Thursday. The company reported C$0.60 EPS for the quarter, FiscalAI reports. The business had revenue of C$18.08 million during the quarter. Cipher Pharmaceuticals had a net margin of 58.81% and a return on equity of 22.74%.

Cipher Pharmaceuticals Stock Performance

Shares of CPH stock opened at C$13.61 on Friday. The company has a current ratio of 1.59, a quick ratio of 2.67 and a debt-to-equity ratio of 0.27. The company has a market cap of C$345.90 million, a PE ratio of 12.15 and a beta of 1.29. The company’s fifty day simple moving average is C$13.77 and its 200-day simple moving average is C$15.73. Cipher Pharmaceuticals has a 52 week low of C$12.76 and a 52 week high of C$20.56.

Insider Activity at Cipher Pharmaceuticals

In related news, Director Craig Mull bought 20,000 shares of the firm’s stock in a transaction dated Friday, September 18th. The stock was bought at an average price of C$14.16 per share, with a total value of C$283,200.00. Following the completion of the transaction, the director directly owned 1,009,953 shares of the company’s stock, valued at approximately C$14,300,934.48. This represents a 2.02% increase in their ownership of the stock. 42.00% of the stock is currently owned by corporate insiders.

Cipher Pharmaceuticals Company Profile

Cipher Pharmaceuticals (TSX: CPH) (OTCQX: CPHRF) is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products. Cipher acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and currently markets those products in Canada, the U.S., and South America.